SCYNEXIS INC. 10-Q Summary: Quarter Ended March 31, 2014
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for SCYNEXIS, Inc., a pharmaceutical company focused on the discovery and development of novel anti-infectives, specifically the lead candidate SCY-078 for invasive fungal infections. The report covers the three-month period ended March 31, 2014. The company operates as a non-accelerated filer and was a private entity at the time of the report, having completed its Initial Public Offering (IPO) on May 7, 2014, shortly after the reporting period.
Key Financial Metrics
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Total Revenue | $4.7 million | $4.8 million |
| Gross Profit | $0.7 million | $0.6 million |
| Net Income (Loss) | $0.4 million | $(2.1) million |
| Net Loss Attributable to Common Stockholders | $(1.2) million | $(2.1) million |
| Cash and Cash Equivalents (End of Period) | $0.7 million | $0.8 million |
| Total Debt (Current Portion) | $15.0 million | $15.0 million |
| Accumulated Deficit | $(112.9) million | $(113.3) million |
Liquidity: As of March 31, 2014, the company held $0.65 million in cash. The company had a working capital deficit, with current liabilities of $20.5 million against current assets of $2.3 million. A significant portion of liabilities included a $10.0 million derivative liability related to warrants.
Material Changes vs. Prior Period
- Net Income vs. Loss: The company reported a net income of $0.4 million in Q1 2014 compared to a net loss of $2.1 million in Q1 2013. This reversal was primarily driven by a non-cash gain of $2.8 million from the fair value adjustment of derivative liabilities (warrants), resulting from a decrease in the estimated fair value of the company's common stock.
- Operating Expenses: Total operating expenses increased by $0.8 million (45.9%) to $2.5 million. This increase was largely due to the absence of a $0.5 million gain on the sale of assets recorded in Q1 2013. Research and Development (R&D) expenses increased by $0.2 million, driven by higher spending on the SCY-078 program ($0.84 million vs. $0.16 million).
- Revenue Stability: Total revenue remained relatively flat, decreasing slightly by 1.9% to $4.7 million. Revenue from related parties (Merial/Sanofi) remained consistent at $1.8 million, representing approximately 39% of total revenue.
- Debt Conversion: Convertible notes outstanding in the prior year were converted into Series D-1 and D-2 preferred stock in December 2013, eliminating related party interest expense for the current quarter.
Outlook, Risks, and Unusual Items
- Subsequent Events (IPO): On May 7, 2014, the company completed an IPO, selling 6.2 million shares at $10.00 per share for net proceeds of approximately $54.8 million. Proceeds were used to pay off the entire $15.0 million credit facility with HSBC Bank and convert all preferred stock to common stock.
- Derivative Liability Volatility: The company estimates an additional non-cash gain of $7.2 million for the second quarter of 2014 due to the further decrease in the estimated fair value of its common stock leading up to the IPO price of $10.00.
- Going Concern: The company has incurred losses since inception and had an accumulated deficit of $112.9 million. While the IPO resolved immediate liquidity concerns, the company expects to continue incurring losses as it advances SCY-078 through clinical trials.
- Key Risks:
- Regulatory Approval: No products are approved for sale; success depends on FDA approval of SCY-078, which is in Phase 2 development.
- Customer Concentration: The company is substantially dependent on its contract with Merial (Sanofi), which expires December 31, 2014, for a significant portion of its revenue.
- Capital Needs: Despite the IPO, the company anticipates needing additional capital to fund operations through at least the first half of 2016.
Investor Verification Checklist
- Revenue Concentration: Verify the status of the contract with Merial (Sanofi), which accounted for 39% of revenue and expires in late 2014.
- Non-GAAP Adjustments: Understand that the reported net income is largely artificial, driven by a $2.8 million non-cash accounting gain on derivatives, not operational profitability.
- Debt Status: Confirm the repayment of the $15 million HSBC credit facility using IPO proceeds, which occurred in May 2014.
- Cash Runway: Assess the sufficiency of the $54.8 million IPO proceeds to fund the development of SCY-078 through the projected timeline (mid-2016).
- Stock Dilution: Review the impact of the reverse stock splits (1-for-4 and 1-for-5.1) and the conversion of preferred stock on share count and ownership structure.